Non-Small Cell Lung Cancer: From Cytotoxic Systemic Chemotherapy to Molecularly Targeted Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Non-Small Cell Lung Cancer: From Cytotoxic Systemic Chemotherapy to Molecularly Targeted Therapy



Anti-Cancer Agents in Medicinal Chemistry, 4(3): 231-245.

Author(s): Alfredo Cesario, Sonya Trombino, Domenico Galetta, Stefano Margaritora, Carmelina Murolo, Lorenzo Dominioni, Andrea Imperatori, Luigi Festi, Pierluigi Granone and Patrizia Russo.

Affiliation: Department of SurgicalScience, Division of General Thoracic Surgery, Catholic University, LargoA. Gemelli, 8, 00168 Roma, Italy

Abstract

Surgery is the only method of cure in lung cancer. Seldom its application with radical intent is possible. Despite the efforts aimed at integrating all the therapeutic strategies, the overall outcome of the management of this disease remains disappointing. For this reason, in the last three decades, thousands of preclinical and clinical attempts have been realised in order to investigate any possible way to cure this disease and significant steps forward have been made on the basis of the increasing “molecular knowledge” in the so called “post-genomic era”. Particularly the impressive step forward in the biological characterization of cancer as a result of genetic / epigenetic multistep process has brought in a multitude of variables with staggering classification potentialities. “Benchside” and “bedside” scientists have assembled in functional teams to move the common efforts “translationally” to bridge basic and clinical research for a mutual synergistic enhancement. This paper represents the effort of a lung cancer focused translational research team made up of molecular biologists, medical oncologists and thoracic surgeons to achieve a comprehensive, but simple, review of the current status of the shift from cytotoxic to molecularly targeted therapy in lung cancer treatment potentially useful in the planning of translational research trials.

Keywords:

Lung Cancer, oncologists, cytotoxic, epigenetic.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 4
Issue Number: 3
First Page: 231
Last Page: 245
Page Count: 15
DOI: 10.2174/1568011043352957
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science